期刊文献+

中西医结合治疗白塞病临床疗效 被引量:1

Clinical effect of integrated traditional Chinese medicine and western medicine in the treatment of Behcet' s disease
下载PDF
导出
摘要 目的探讨中西医结合治疗白塞病的临床治疗方案及其疗效。方法回顾性分析本院门诊收治的30例中西医结合治疗白塞病患者的临床资料。结果 30例患者经过精心的中西医结合治疗后,控制18例,好转9例,无效3例,总有效率为90.0%。结论中西医结合治疗白塞病临床效果显著,毒副作用小,可以有效提高治愈率,降低复发率。 Objective To investigate clinical effect of integrated traditional Chinese and western medicine in the treatment of Behcet's disease. Methods From January 2010 to October, clinical data of 30 cases of Behcet's disease treated by integrated Chinese medicine and western medicine were analyzed. Results 30 patients after carefully integrated Chinese and western medicine treatment, 18 cases controlled, 9 cases improved, 3 cases ineffective, the total effective rate was 90%. Conclusion Integrated traditional Chinese medicine and western medicine has a significant clinical effect in the treatment of Behcet's disease with small toxic and side effect, which can effectively improve cure rate, relapse rate.
作者 朱琳 陈鹏
出处 《中国实用医药》 2014年第18期30-31,共2页 China Practical Medicine
关键词 中西医结合 白塞病 临床疗效 Integrated traditional Chinese medicine and western medicine Behcet's disease Clinical effect
  • 相关文献

参考文献4

二级参考文献10

  • 1Vasiliauskas EA,Kam LY,Abreu-Martin MT,et al.An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease[].Gastroenterology.1999
  • 2Papadakis KT,Targan SR.Tumor necrosis factor: biology and therapeutic inhibitors[].Gastroenterology.2000
  • 3Sandborn WJ,Hanauer SB.Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety[].Inflammatory Bowel Diseases.1999
  • 4Schreiber S,Rutgeerts P,Fedorak R,et al.CDP870,a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn’s disease(CD)[].Gastroenterology.2003
  • 5Sandborn WJ,Hanauer SB,Katz S.Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial[].Gastroenterology.2001
  • 6D’Haens G,Swijsen C,Noman M,et al.Etanercept in the treatment of active refractory Crohn’s disease: a single-center pilot trial[].The American journal of Gastroenterology.2001
  • 7Hommes D,van den Blink B,Plasse T,ef al.Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease[].Gastroenterology.2002
  • 8Murch SH,Braegger CP,Walker-Smith JA,et al.Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory boweldisease[].Gut.1993
  • 9Rutgeerts P,Lemmens L,van Assche G,ef al.Recombinant soluble p55 receptor induces remission, is non-immunogenic and well tolerated in active Crohn’s disease: results of a randomized pilot trial[].Gastroenterology.2001
  • 10Salituro FG,Germann UA,Wilson KP,ef al.Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases[].Current Medical Chemistry.1999

共引文献12

同被引文献24

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部